Form 4: AN2 Therapeutics Executive Joshua M. Eizen Reports Stock and Option Grants

Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, reported the grant of stock and option awards.

Summary

• On November 4, 2024, Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, received a grant of 31,500 restricted stock units (RSUs).
• These RSUs vest in equal annual installments over four years, starting November 4, 2024, and ending November 4, 2028, contingent upon continuous service.
• Eizen also received an option to purchase 63,000 shares of common stock at an exercise price of $1.08 per share.
• These options vest monthly over four years, starting November 4, 2024, and ending November 4, 2028, also contingent upon continuous service.
• Following these transactions, Eizen directly owns 126,335 shares of AN2 Therapeutics common stock, which includes previously granted RSUs and shares purchased under the Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants to an executive, which is a common practice for incentivizing management.

Positives

• The grant of RSUs and stock options to a key executive aligns their interests with the long-term success of the company.
• The vesting schedules for both RSUs and stock options incentivize continued service and contribution from the executive.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade in their company's stock. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

• The grant of equity to executives can align their interests with those of shareholders, potentially leading to increased company value.

Key Dates